{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:31:40Z","timestamp":1786516300437,"version":"build-2736575974"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the efficacy and safety of IL-23 p19 monoclonal antibodies for moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to 21 February 2026. We included randomized controlled trials of guselkumab, risankizumab, tildrakizumab, or mirikizumab. Efficacy outcomes were PASI75, PASI90, PASI100, and IGA\/PGA\/sPGA 0\/1; safety outcomes were overall adverse events (AEs) and serious adverse events (SAEs). Risk of bias was assessed using RoB 2.\u00a0A Bayesian network meta-analysis generated odds ratios (ORs) and 95% credible intervals (CrIs), with SUCRA, transitivity, heterogeneity, leave-one-out, and publication-bias assessments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirteen articles comprising 15 RCTs or independent study units were included. Networks were largely placebo-centred, with limited direct active-agent comparisons. Versus placebo, all four agents significantly improved PASI75, PASI100, and IGA\/PGA\/sPGA 0\/1. For PASI90, risankizumab, guselkumab, and mirikizumab were superior to placebo, whereas the tildrakizumab CrI crossed the null. PASI75 ORs versus placebo were 124.04 for risankizumab, 105.41 for guselkumab, 72.36 for mirikizumab, and 24.05 for tildrakizumab. Corresponding ORs for IGA\/PGA\/sPGA 0\/1 were 89.73, 68.84, 52.82, and 21.46. Most comparisons among risankizumab, guselkumab, and mirikizumab were not statistically significant; tildrakizumab showed lower PASI75 and IGA\/PGA\/sPGA 0\/1 responses. SUCRA generally ranked risankizumab highest or near highest, followed by guselkumab and mirikizumab, with tildrakizumab lower. No agent differed significantly from placebo in AE or SAE risk. Sensitivity analyses supported stable efficacy findings, and Egger\u2019s tests found no clear publication bias.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IL-23 p19 antibodies improve skin-clearance outcomes without a clear increase in overall AE or SAE risk. Risankizumab had the most favourable ranking probability, but limited direct evidence and overlapping CrIs preclude definitive superiority claims. Biologic selection should also consider prior treatment, comorbidities, dosing, access, and patient preference. Head-to-head trials and long-term real-world studies are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO<\/jats:ext-link>\n                      , identifier CRD420261382915.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1873488","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:59:38Z","timestamp":1786514378000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and safety of IL-23 p19 monoclonal antibodies for plaque psoriasis: a bayesian network meta-analysis of randomized controlled trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Tong","family":"Xin","sequence":"first","affiliation":[{"name":"Shandong College of Traditional Chinese Medicine","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Sun","sequence":"additional","affiliation":[{"name":"Shandong College of Traditional Chinese Medicine","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihui","family":"Liu","sequence":"additional","affiliation":[{"name":"Shandong College of Traditional Chinese Medicine","place":["Yantai, Shandong, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.18773\/austprescr.2025.026","article-title":"Psoriasis: an update on topical and systemic therapies","volume":"48","author":"Chan","year":"2025","journal-title":"Aust Prescr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880201","article-title":"Epidemiology of psoriasis and comorbid diseases: a narrative review","volume":"13","author":"Bu","year":"2022","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","article-title":"The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study","volume":"8","author":"Damiani","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01423-0","article-title":"Biologics for the treatment of moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis","volume":"15","author":"Lebwohl","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/T(H) 17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ptt.s98893","article-title":"Targeting IL-23 in psoriasis: current perspectives","volume":"8","author":"Fotiadou","year":"2018","journal-title":"Psoriasis (Auckl)"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2438803","DOI":"10.1080\/09546634.2024.2438803","article-title":"Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe","volume":"36","author":"St\u00e4nder","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02568-0","article-title":"Safety of IL-23 p19 inhibitors for the treatment of patients with moderate-to-severe plaque psoriasis: a narrative review","volume":"40","author":"Blauvelt","year":"2023","journal-title":"Adv Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/ccid.s364640","article-title":"Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ed000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/0272989x13487604","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7326\/m14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1501646","article-title":"A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis","volume":"373","author":"Gordon","year":"2015","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16236","article-title":"Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study","volume":"178","author":"Nemoto","year":"2018","journal-title":"Br J Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14941","article-title":"Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial","volume":"46","author":"Ohtsuki","year":"2019","journal-title":"J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0723","article-title":"Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial","volume":"156","author":"Blauvelt","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13932","article-title":"Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002873","article-title":"Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: a 12-week randomized placebo-controlled phase III trial with long-term extension","volume":"137","author":"Yu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(23)00120-0","article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study","volume":"5","author":"Papp","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br J Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/bjd.17628","article-title":"Efficacy and safety of mirikizumab (LY3074828) in the treatment of moderate-to-severe plaque psoriasis: results from a randomized phase II study","volume":"181","author":"Reich","year":"2019","journal-title":"Br J Dermatol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: a comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00475-8","article-title":"Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations","volume":"11","author":"Gisondi","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B35","article-title":"Long-term efficacy of guselkumab for the treatment of moderate-to-severe psoriasis: results from the phase 3 VOYAGE 1 trial through two years","volume":"17","author":"Griffiths","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.040","article-title":"Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials","volume":"82","author":"Reich","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16521","article-title":"Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies","volume":"34","author":"Strober","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.3617","article-title":"Effect of risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials","volume":"156","author":"Augustin","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18232","article-title":"Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19866","article-title":"Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)","volume":"185","author":"Thaci","year":"2021","journal-title":"Br J Dermatol"},{"key":"B41","unstructured":"OMVOH (Mirikizumab-Mrkz) Prescribing Information"},{"key":"B42","unstructured":"Omvoh: EPAR Product Information"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220868","article-title":"Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response","volume":"14","author":"Sawyer","year":"2019","journal-title":"PloS One"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1591787","article-title":"Efficacy and safety of mirikizumab (LY3074828) in chronic plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Ashraf","year":"2025","journal-title":"Front Med (Lausanne)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1873488\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:59:40Z","timestamp":1786514380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1873488\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":46,"alternative-id":["10.3389\/fimmu.2026.1873488"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1873488","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1873488"}}